FY2025 · ended Dec 31, 2025 · Revenue $62.58B, -1.6% YoY · Filed Feb 26, 2026
Pfizer Inc (PFE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $62.6 billion and net income of $7.8 billion. Free cash flow was $9.1 billion. As of Sep 27, 2026 it held $10.9 billion in cash and investments and $62.6 billion in total debt.
Revenue (TTM)
$63.62B
+1.3% vs year-ago TTM
Net income (TTM)
$4.03B
-59.0% vs year-ago TTM
Operating cash flow (TTM)
$14.17B
+8.4% vs year-ago TTM
Free cash flow (TTM)
$11.79B
+13.6% vs year-ago TTM
EPS (TTM)
$0.70
-59.2% vs year-ago TTM
Dividend per share (TTM)
$1.72
+0.6% vs year-ago TTM
Shares outstanding
5.69B
+0.3% vs prior year
Net cash
$-51.66B
as of Sep 27, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PFE (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 78003
- Former names
- PFIZER INC (until Nov 3, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $62.6B | $63.6B | $59.6B | $101.2B | $73.6B |
| Net income | $7.8B | $8.0B | $2.1B | $31.4B | $22.0B |
| Diluted EPS | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
| Operating cash flow | $11.7B | $12.7B | $8.7B | $29.3B | $32.6B |
| Free cash flow | $9.1B | $9.8B | $4.8B | $26.0B | $29.9B |
| Total assets | $208.2B | $213.4B | $226.5B | $197.2B | $181.5B |
| Total liabilities | $121.4B | $124.9B | $137.2B | $101.3B | $104.0B |
| Stockholders' equity | $86.5B | $88.2B | $89.0B | $95.7B | $77.2B |
| Cash and investments | $10.3B | $11.9B | $22.6B | $34.2B | $45.5B |
| Total debt | $67.3B | $66.2B | $74.9B | $38.7B | $40.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Oct 30, 2026 |
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 27, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2026 | Jun 18, 2026 |
All 1000 Pfizer Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.